Despite resilient demand, healthcare has taken a hit along with the rest of the market. This Big Pharma could boost profits ...

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

What should investors do when stocks are tanking over the short term? Three Motley Fool contributors think they've found ...

As of Monday, the Nasdaq Composite index had tumbled more than 11% since the start of the year. On the contrary -- this can ...

Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary ...

Though the company's leading candidate in this field, MariTide, didn't quite live up to market expectations in a phase 2 clinical trial, it's too early to give up on this project. The company is ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

There is also anticipation building for MariTide, its experimental obesity drug entering phase 3 trials, which could position ...

There is also anticipation building for MariTide, its experimental obesity drug entering phase 3 trials, which could position the company to enter the GLP-1 weight loss and diabetes market.

In November, Amgen announced 52-week top-line data from a phase II study on MariTide, its GLP-1 therapy for obesity. The data showed that the drug led to approximately 20% average weight loss over ...